Sanofi India Limited (SANOFI.NS)
INR 6082.6
(-0.65%)
INR 6082.6
(-0.65%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 16.32 Billion INR | -21.55% |
| 2022 | 15.8 Billion INR | -2.31% |
| 2021 | 16.17 Billion INR | 0.16% |
| 2020 | 16.15 Billion INR | -3.07% |
| 2019 | 16.66 Billion INR | 4.39% |
| 2018 | 15.96 Billion INR | 11.0% |
| 2017 | 14.38 Billion INR | 12.77% |
| 2016 | 12.75 Billion INR | 9.85% |
| 2015 | 11.6 Billion INR | 17.47% |
| 2014 | 9.88 Billion INR | 0.85% |
| 2013 | 9.8 Billion INR | 18.01% |
| 2012 | 8.3 Billion INR | 36.05% |
| 2011 | 6.1 Billion INR | 11.8% |
| 2010 | 5.45 Billion INR | 10.87% |
| 2009 | 4.92 Billion INR | -2.87% |
| 2008 | 5.07 Billion INR | 12.42% |
| 2007 | 4.51 Billion INR | -0.94% |
| 2006 | 4.55 Billion INR | 5.31% |
| 2005 | 4.32 Billion INR | 6.82% |
| 2004 | 4.04 Billion INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 3.21 Billion INR | 3.24% |
| 2024 Q2 | 1.73 Billion INR | -46.14% |
| 2023 Q1 | 4.31 Billion INR | 10.52% |
| 2023 FY | 12.39 Billion INR | -21.55% |
| 2023 Q2 | 3.89 Billion INR | -9.75% |
| 2023 Q4 | 3.11 Billion INR | -24.9% |
| 2023 Q3 | 4.14 Billion INR | 6.41% |
| 2022 FY | 15.8 Billion INR | -2.31% |
| 2022 Q2 | 3.79 Billion INR | -6.75% |
| 2022 Q3 | 4.02 Billion INR | 6.0% |
| 2022 Q4 | 3.9 Billion INR | -2.93% |
| 2022 Q1 | 4.07 Billion INR | 17.21% |
| 2021 Q1 | 4 Billion INR | 7.97% |
| 2021 Q3 | 4.22 Billion INR | -5.57% |
| 2021 Q4 | 3.47 Billion INR | -17.71% |
| 2021 Q2 | 4.47 Billion INR | 11.58% |
| 2021 FY | 16.17 Billion INR | 0.16% |
| 2020 FY | 16.15 Billion INR | -3.07% |
| 2020 Q4 | 3.71 Billion INR | -8.5% |
| 2020 Q3 | 4.05 Billion INR | 2.97% |
| 2020 Q2 | 3.94 Billion INR | -11.32% |
| 2020 Q1 | 4.44 Billion INR | 8.58% |
| 2019 Q4 | 4.09 Billion INR | -7.23% |
| 2019 Q1 | 4.09 Billion INR | 12.5% |
| 2019 Q2 | 4.06 Billion INR | -0.66% |
| 2019 Q3 | 4.41 Billion INR | 8.46% |
| 2019 FY | 16.66 Billion INR | 4.39% |
| 2018 Q2 | 4.08 Billion INR | 11.09% |
| 2018 Q4 | 3.63 Billion INR | -16.25% |
| 2018 FY | 15.96 Billion INR | 11.0% |
| 2018 Q1 | 3.68 Billion INR | -7.33% |
| 2018 Q3 | 4.34 Billion INR | 6.29% |
| 2017 Q3 | 4.18 Billion INR | 18.39% |
| 2017 Q2 | 3.53 Billion INR | 11.09% |
| 2017 Q1 | 3.18 Billion INR | 5.33% |
| 2017 FY | 14.38 Billion INR | 12.77% |
| 2017 Q4 | 3.97 Billion INR | -5.11% |
| 2016 Q4 | 3.02 Billion INR | -8.92% |
| 2016 FY | 12.75 Billion INR | 9.85% |
| 2016 Q3 | 3.31 Billion INR | 1.16% |
| 2016 Q2 | 3.27 Billion INR | 8.68% |
| 2016 Q1 | 3.01 Billion INR | 12.11% |
| 2015 Q3 | 3.2 Billion INR | 13.05% |
| 2015 FY | 11.6 Billion INR | 17.47% |
| 2015 Q4 | 2.69 Billion INR | -16.06% |
| 2015 Q1 | 2.49 Billion INR | 6.1% |
| 2015 Q2 | 2.83 Billion INR | 13.9% |
| 2014 Q2 | 2.59 Billion INR | 11.96% |
| 2014 Q3 | 2.62 Billion INR | 1.2% |
| 2014 FY | 9.88 Billion INR | 0.85% |
| 2014 Q4 | 2.34 Billion INR | -10.59% |
| 2014 Q1 | 2.31 Billion INR | -10.16% |
| 2013 Q4 | 2.57 Billion INR | -5.36% |
| 2013 Q2 | 2.36 Billion INR | 5.82% |
| 2013 Q1 | 2.23 Billion INR | -18.12% |
| 2013 FY | 9.8 Billion INR | 18.01% |
| 2013 Q3 | 2.72 Billion INR | 15.32% |
| 2012 Q3 | 2.04 Billion INR | 8.31% |
| 2012 Q4 | 2.72 Billion INR | 33.23% |
| 2012 Q2 | 1.89 Billion INR | 1.72% |
| 2012 Q1 | 1.85 Billion INR | 11.8% |
| 2012 FY | 8.3 Billion INR | 36.05% |
| 2011 Q2 | 1.52 Billion INR | 0.0% |
| 2011 Q4 | 1.66 Billion INR | 9.47% |
| 2011 Q3 | 1.51 Billion INR | -0.26% |
| 2011 FY | 6.1 Billion INR | 11.8% |
| 2010 FY | 5.45 Billion INR | 10.87% |
| 2009 FY | 4.92 Billion INR | -2.87% |
| 2008 FY | 5.07 Billion INR | 12.42% |
| 2007 FY | 4.51 Billion INR | -0.94% |
| 2006 FY | 4.55 Billion INR | 5.31% |
| 2005 FY | 4.32 Billion INR | 6.82% |
| 2004 FY | 4.04 Billion INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Abbott India Limited | 26.16 Billion INR | 37.609% |
| Cipla Limited | 161.81 Billion INR | 89.911% |
| Gland Pharma Limited | 16.6 Billion INR | 1.668% |
| GlaxoSmithKline Pharmaceuticals Limited | 12.82 Billion INR | -27.339% |
| Kopran Limited | 2.12 Billion INR | -667.684% |
| Marksans Pharma Limited | 7.71 Billion INR | -111.635% |
| NGL Fine-Chem Limited | 1.23 Billion INR | -1224.613% |
| Pfizer Limited | 9.9 Billion INR | -64.812% |
| SMS Pharmaceuticals Limited | 2.1 Billion INR | -673.935% |
| TTK Healthcare Limited | 2.68 Billion INR | -507.682% |